143 related articles for article (PubMed ID: 37126153)
21. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
[TBL] [Abstract][Full Text] [Related]
22. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
23. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
24. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
Stephens JM; Bensink M; Bowers C; Hollenbeak CS
Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043
[TBL] [Abstract][Full Text] [Related]
25. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment.
Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
Curr Med Res Opin; 2019 Jun; 35(6):1073-1080. PubMed ID: 30550346
[TBL] [Abstract][Full Text] [Related]
26. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
Fernandes R; Mazzarello S; Stober C; Vandermeer L; Dudani S; Ibrahim MF; Majeed H; Perdrizet K; Shorr R; Hutton B; Fergusson D; Clemons M
Breast Cancer Res Treat; 2017 Jan; 161(1):1-10. PubMed ID: 27783280
[TBL] [Abstract][Full Text] [Related]
27. Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer.
Suzuki K; Sasada S; Kimura Y; Emi A; Kadoya T; Okada M
Anticancer Res; 2022 Dec; 42(12):5945-5949. PubMed ID: 36456134
[TBL] [Abstract][Full Text] [Related]
28. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
[TBL] [Abstract][Full Text] [Related]
29. Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.
Chan A; Fu WH; Shih V; Coyuco JC; Tan SH; Ng R
Support Care Cancer; 2011 Apr; 19(4):497-504. PubMed ID: 20232087
[TBL] [Abstract][Full Text] [Related]
30. Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Kawahira M; Yokota T; Hamauchi S; Kawai S; Yoshida Y; Onozawa Y; Tsushima T; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
Int J Clin Oncol; 2018 Dec; 23(6):1189-1195. PubMed ID: 29948238
[TBL] [Abstract][Full Text] [Related]
31. Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.
Van Belle H; Hurvitz SA; Gilbar PJ; Wildiers H
Breast Cancer Res Treat; 2021 Dec; 190(3):357-372. PubMed ID: 34533681
[TBL] [Abstract][Full Text] [Related]
32. The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity.
Kushnir I; Koczka K; Ong M; Canil C; Bossé D; Sabri E; Reaume MN
Med Oncol; 2019 Jan; 36(2):18. PubMed ID: 30666463
[TBL] [Abstract][Full Text] [Related]
33. Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan.
Kosaka T; Uemura H; Sumitomo M; Harada K; Sugimoto M; Hayashi N; Yoshimura K; Fukasawa S; Ecstein-Fraisse E; Sunaga Y; Oya M
Jpn J Clin Oncol; 2019 Aug; 49(8):766-771. PubMed ID: 31329922
[TBL] [Abstract][Full Text] [Related]
34. Effect of 3 mg versus 6 mg pegfilgrastim on the prevention of febrile neutropenia in breast cancer patients receiving docetaxel and cyclophosphamide: a retrospective study.
Zhang Z; Li H; Zhang J; Ye X; Liu H; Zhai Q; Yu B; Du Q
Ann Palliat Med; 2021 May; 10(5):5310-5315. PubMed ID: 33977742
[TBL] [Abstract][Full Text] [Related]
35. Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.
Lavoie JM; Zou K; Khalaf D; Eigl BJ; Kollmannsberger CK; Vergidis J; Noonan K; Zulfiqar M; Finch D; Chi KN
Prostate; 2019 Feb; 79(3):281-287. PubMed ID: 30370697
[TBL] [Abstract][Full Text] [Related]
36. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Do T; Medhekar R; Bhat R; Chen H; Niravath P; Trivedi MV
Breast Cancer Res Treat; 2015 Oct; 153(3):591-7. PubMed ID: 26337685
[TBL] [Abstract][Full Text] [Related]
37. Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort study.
Kwok CCH; Wong WH; Chan LL; Wong SPY; Wang F; Wong MCS; Tse SLA
Hong Kong Med J; 2022 Dec; 28(6):438-446. PubMed ID: 36261264
[TBL] [Abstract][Full Text] [Related]
38. Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer.
Kreis K; Horenkamp-Sonntag D; Schneider U; Zeidler J; Glaeske G; Weissbach L
BJU Int; 2022 Apr; 129(4):470-479. PubMed ID: 34242474
[TBL] [Abstract][Full Text] [Related]
39. Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada.
Shayegan B; Wallis CJD; Hamilton RJ; Morgan SC; Cagiannos I; Basappa NS; Ferrario C; Gotto GT; Fernandes R; Roy S; Noonan KL; Niazi T; Hotte SJ; Saad F; Hew H; Park-Wyllie L; Chan KFY; Malone S
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):74-79. PubMed ID: 35197558
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.
van Dooijeweert C; van der Wall E; Baas IO
Neth J Med; 2019 Dec; 77(9):310-316. PubMed ID: 31814585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]